2023煙臺(tái)年中考·快訊 | 英文版：高新區(qū)博安生物創(chuàng)新藥全產(chǎn)業(yè)鏈項(xiàng)目 打破多項(xiàng)技術(shù)壁壘

　　高新區(qū)博安生物創(chuàng)新藥全產(chǎn)業(yè)鏈項(xiàng)目：打破多項(xiàng)技術(shù)壁壘

　　Boan Biotech Innovative Drug Industry Chain Project of Gaoxin (High-tech) District :

　　Break a Number of Technical Barriers

　　博安生物是綠葉集團(tuán)旗下第二家上市公司，聚焦腫瘤、免疫等疾病，進(jìn)行生物藥的開發(fā)、生產(chǎn)和商業(yè)化。項(xiàng)目總投資30億元，占地85畝，一期2021年4月投產(chǎn)，二期2024年竣工達(dá)產(chǎn)，預(yù)計(jì)今年產(chǎn)值超過十億，5年產(chǎn)值將突破百億。作為高新區(qū)本土孵化培育的2022年香港主板上市企業(yè)，“蝶變”之路，展現(xiàn)了高新區(qū)生物醫(yī)藥產(chǎn)業(yè)“研發(fā)-中試-產(chǎn)業(yè)化”的全鏈條成長(zhǎng)規(guī)律。

　　Boan Biotech is the second listed company under Luye Pharma, which focuses on the development, production and commercialization of biological drugs for cancer, immunity and other related diseases. The total investment of the project is 3 billion yuan, covering an area of 85 acres. The first phase has been put into operation since April 2021, while the second phase will be completed in 2024, and the output value is expected to exceed 1 billion this year and will exceed 10 billion in 5 years. As a company listed on the main board of Hong Kong in 2022, its journey towards a metamorphosis shows a whole-chain growth of Gaoxin (high-tech) Distric, which follows the path of R&D, pilot test, industrialization.

　　深耕研發(fā)，培根筑基。累計(jì)研發(fā)投入超過20億，帶動(dòng)企業(yè)井噴式發(fā)展，目前開發(fā)12款生物藥，2款已在國(guó)內(nèi)上市、4款正在進(jìn)行上市沖刺、6款進(jìn)入臨床，研發(fā)速度全國(guó)第一。其中，博優(yōu)倍為全球首個(gè)獲批上市的地舒單抗生物類似藥，被評(píng)為“2022年中國(guó)醫(yī)藥生物技術(shù)十大進(jìn)展”。

　　With deep research and development, solid roots and foundation, the project has an accumulative investment of more than 2 billion, which drives its soaring development. Currently, it has developed 12 biological drugs with 2 have come into domestic market and 4 getting prepared. Another 6 already go into clinic trial, the research and development speed ranks top across the country. Among them, Boyoubi is the world's first disuzumab biosimilar drug that is approved to go into the market and was rated as one of the Top 10 Pharmaceutical Biotechnology Progress of China in 2022.

　　強(qiáng)建平臺(tái)，賦能加速。搭建三大自主創(chuàng)新技術(shù)平臺(tái)，其中，全人抗體轉(zhuǎn)基因小鼠技術(shù)平臺(tái)是國(guó)內(nèi)首創(chuàng)、業(yè)內(nèi)最好的小鼠平臺(tái)，通過將人的抗體基因片段植入小鼠體內(nèi)，使小鼠直接產(chǎn)生人類抗體，藥品研發(fā)成功率提升3倍，研發(fā)周期縮短1/2。

　　A strong platform shall enable the acceleration of development. It has three independent-built innovation technology platforms , among which, the whole-human antibody transgenic mouse technology platform is the first mouse platform in China and the best within the industry. By implanting human antibody gene fragments into mice, mice can directly produce human antibodies, increasing the success rate of drug research and development by 3 times and shortening the research and development cycle by 1/2.

　　布局全球，引才聚智。在美國(guó)、日本、德國(guó)、新加坡等世界醫(yī)藥領(lǐng)先地區(qū)布局研發(fā)機(jī)構(gòu)，建立了與全球先進(jìn)技術(shù)接軌的國(guó)際化專業(yè)團(tuán)隊(duì)，擁有國(guó)際高層次人才領(lǐng)銜的研發(fā)人員285人，碩博占比85%以上，強(qiáng)大的人才團(tuán)隊(duì)打破多項(xiàng)技術(shù)壁壘，獲得國(guó)內(nèi)外發(fā)明專利31項(xiàng)、待批專利45項(xiàng)，在細(xì)胞株培養(yǎng)方面攻克了國(guó)外“卡脖子”技術(shù)，實(shí)現(xiàn)國(guó)產(chǎn)替代；在實(shí)體瘤抗體技術(shù)方面位居全球第二、中國(guó)第一，實(shí)現(xiàn)從追趕者到領(lǐng)跑者的跨越。

　　Laying out globally shall gather talents and wisdom. By establishing R&D institutions in United States, Japan, Germany, Singapore and other pharmaceutically leading areas of the world, Boan Biotech has set up professional teams in line with world's advanced technology. With 285 high-level international R&D personnel, 85% of whom own master or doctoral degrees, this strong talent team has broken a number of technical barriers, obtained 31 domestic and foreign invention patents and another 45 pending for approval. In terms of cell strain culture, they overcome choke-point technology and replaced foreign solution with domestic substitution. In terms of solid tumor antibody technology, it ranks second in the world and first in China, achieving a leap from a pursuer to a leader.

　　博安生物已進(jìn)入高速成長(zhǎng)期，市區(qū)兩級(jí)將繼續(xù)在孵化場(chǎng)地、研發(fā)投入、人才獎(jiǎng)勵(lì)、資本加持等方面全力賦能，加快推動(dòng)博洛佳、度拉糖肽等10款創(chuàng)新藥，60余款2類及以上醫(yī)療器械獲批上市，為“創(chuàng)新好藥煙臺(tái)制造”金字招牌貢獻(xiàn)“高新”力量。

　　Boan Biotech has entered a high-speed growth period, both city and district administrations will continue to fully support the project in terms of offering incubation sites, research and development investment, talent rewards, financial aids and so on, to accelerate the promotion of 10 innovative drugs and help with more than 60 type-2 and above medical devices get approved for the market, contributing its own forces for made-in-Yantai innovative good drug.